Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559940400> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2559940400 endingPage "298" @default.
- W2559940400 startingPage "289" @default.
- W2559940400 abstract "Nonadherence to medication is a major problem for patients with schizophrenia. To counter this problem, pharmaceutical companies began developing depot antipsychotics. Although there are currently 5 first-generation and 6 second-generation depot antipsychotics available worldwide, many physicians are still reluctant to use this category of drug initially. This review provides the latest information about the use of depot antipsychotics in schizophrenia treatment as well as several studies in support of depot antipsychotic use as first-line treatment for patients with schizophrenia.A systematic review of 4 milestone schizophrenia studies was performed to provide an aggregate analysis of the history and use of depot antipsychotics. Results and findings from several clinical trials--the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), European First Episode Schizophrenia Trial (EUFEST), A Comparison of Long-Acting Injectable Medications for Schizophrenia (ACLAIMS), and Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE)--were summarized to provide more information on the development and evolution of depot antipsychotics, common factors that contribute to nonadherence, and guidelines for each long-acting injectable currently available.The CATIE schizophrenia study revealed a 74% rate of discontinuation of oral antipsychotics within 6 months of use. Similar findings from the EUFEST study indicated that 42% of participants discontinued oral medications after 12 months of use. The ACLAIMS study reported no statistically significant difference in efficacy failure rate between haloperidol decanoate and paliperidone palmitate. The PRIDE study found that first hospitalization or arrest was 43% higher among patients in the oral antipsychotic group vs the depot group during the study.This review provides clinical evidence to support the use of depot formulations as first-line treatment for patients with schizophrenia, which may improve adherence and thereby lower risk of relapse, suicide, rehospitalization, and incarceration." @default.
- W2559940400 created "2016-12-16" @default.
- W2559940400 creator A5030809364 @default.
- W2559940400 creator A5031455553 @default.
- W2559940400 creator A5078707856 @default.
- W2559940400 creator A5082274214 @default.
- W2559940400 date "2016-11-01" @default.
- W2559940400 modified "2023-09-23" @default.
- W2559940400 title "Depot antipsychotics: Where do we stand?" @default.
- W2559940400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27901520" @default.
- W2559940400 hasPublicationYear "2016" @default.
- W2559940400 type Work @default.
- W2559940400 sameAs 2559940400 @default.
- W2559940400 citedByCount "1" @default.
- W2559940400 countsByYear W25599404002017 @default.
- W2559940400 crossrefType "journal-article" @default.
- W2559940400 hasAuthorship W2559940400A5030809364 @default.
- W2559940400 hasAuthorship W2559940400A5031455553 @default.
- W2559940400 hasAuthorship W2559940400A5078707856 @default.
- W2559940400 hasAuthorship W2559940400A5082274214 @default.
- W2559940400 hasConcept C118552586 @default.
- W2559940400 hasConcept C166957645 @default.
- W2559940400 hasConcept C187212893 @default.
- W2559940400 hasConcept C2776412080 @default.
- W2559940400 hasConcept C2776561332 @default.
- W2559940400 hasConcept C2777126507 @default.
- W2559940400 hasConcept C2778715236 @default.
- W2559940400 hasConcept C2780057945 @default.
- W2559940400 hasConcept C2780494398 @default.
- W2559940400 hasConcept C2780864610 @default.
- W2559940400 hasConcept C2908997079 @default.
- W2559940400 hasConcept C71924100 @default.
- W2559940400 hasConcept C95457728 @default.
- W2559940400 hasConceptScore W2559940400C118552586 @default.
- W2559940400 hasConceptScore W2559940400C166957645 @default.
- W2559940400 hasConceptScore W2559940400C187212893 @default.
- W2559940400 hasConceptScore W2559940400C2776412080 @default.
- W2559940400 hasConceptScore W2559940400C2776561332 @default.
- W2559940400 hasConceptScore W2559940400C2777126507 @default.
- W2559940400 hasConceptScore W2559940400C2778715236 @default.
- W2559940400 hasConceptScore W2559940400C2780057945 @default.
- W2559940400 hasConceptScore W2559940400C2780494398 @default.
- W2559940400 hasConceptScore W2559940400C2780864610 @default.
- W2559940400 hasConceptScore W2559940400C2908997079 @default.
- W2559940400 hasConceptScore W2559940400C71924100 @default.
- W2559940400 hasConceptScore W2559940400C95457728 @default.
- W2559940400 hasIssue "4" @default.
- W2559940400 hasLocation W25599404001 @default.
- W2559940400 hasOpenAccess W2559940400 @default.
- W2559940400 hasPrimaryLocation W25599404001 @default.
- W2559940400 hasRelatedWork W14166098 @default.
- W2559940400 hasRelatedWork W1551052972 @default.
- W2559940400 hasRelatedWork W1980087204 @default.
- W2559940400 hasRelatedWork W2032940209 @default.
- W2559940400 hasRelatedWork W2400728488 @default.
- W2559940400 hasRelatedWork W2489004988 @default.
- W2559940400 hasRelatedWork W2794112983 @default.
- W2559940400 hasRelatedWork W3102273891 @default.
- W2559940400 hasRelatedWork W3119476510 @default.
- W2559940400 hasRelatedWork W72903313 @default.
- W2559940400 hasVolume "28" @default.
- W2559940400 isParatext "false" @default.
- W2559940400 isRetracted "false" @default.
- W2559940400 magId "2559940400" @default.
- W2559940400 workType "article" @default.